Physician profile
William Pittas
NPI 1639263098
$2,556.76
in general payments reported to CMS, 2019-2025
14 companies · $1,479 in 2025
The $1,479 reported for 2025 was more than what 78% of Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $66.69 · 2021: $74.26 · 2022: $110 · 2023: $297 · 2024: $421 · 2025: $1,479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,659 · Travel and Lodging: $538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,659.05 |
| Travel and Lodging | $537.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axogen | $1,212.61 | 2024-2025 | Axoguard Nerve Connector, Avance Nerve Graft, Axoguard Nerve Protector |
| Abbvie INC. | $736.82 | 2023-2025 | |
| Allergan, INC. | $170.24 | 2019-2022 | |
| Mentor Worldwide LLC | $142.01 | 2019-2025 | Mentor Memorygel Resterilizable Gel Sizer |
| Smith+Nephew, INC. | $78.54 | 2019-2021 | |
| Integra Lifesciences Corporation | $51.00 | 2023 | Integra, Integra Dermal Regeneration Template, Omnigraft |
| Kerecis Limited | $35.98 | 2020-2021 | |
| Biofrontera INC. | $25.92 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Solventum Corporation | $18.68 | 2024 | Prevena |
| Musculoskeletal Transplant Foundation INC. | $18.41 | 2024 | |
| Janssen Biotech, INC. | $17.20 | 2023 | Tremfya |
| Apollo Endosurgery US INC | $16.95 | 2022 | |
| Motiva USA, LLC | $16.42 | 2025 | |
| Genzyme Corporation | $15.98 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Pittas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.